专题：Chronic Myeloid Leukemia Treatments

This cluster of papers focuses on the efficacy and resistance of various tyrosine kinase inhibitors, such as Imatinib, Dasatinib, and Nilotinib, in the treatment of Chronic Myeloid Leukemia (CML). The papers discuss molecular mechanisms of resistance, mutation analysis, leukemia stem cells, treatment discontinuation, and long-term outcomes of different targeted therapies.
最新文献
LBA5 Zongertinib in patients with HER2-mutant NSCLC: Updated analysis of beamion LUNG-1

article Full Text OpenAlex

Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma

article Full Text OpenAlex

Concurrent inhibition of p300/CBP and FLT3 enhances cytotoxicity and overcomes resistance in acute myeloid leukemia

article Full Text OpenAlex

Advancing Src kinase inhibition: From structural design to therapeutic innovation - A comprehensive review

review Full Text OpenAlex

Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial

article Full Text OpenAlex

Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

article Full Text OpenAlex

Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations

review Full Text OpenAlex

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review

review Full Text OpenAlex

Analyzing Two Decades of Leukemia Mortality in the U.S. (1999-2020)

article Full Text OpenAlex

Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3–internal tandem duplications in the QuANTUM-First trial

article Full Text OpenAlex

近5年高被引文献
Kinase drug discovery 20 years after imatinib: progress and future directions

review Full Text OpenAlex 950 FWCI142.58391616

Trends in kinase drug discovery: targets, indications and inhibitor design

review Full Text OpenAlex 690 FWCI99.32603535

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease

article Full Text OpenAlex 435 FWCI58.52649005

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

article Full Text OpenAlex 382 FWCI149.03428979

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

review Full Text OpenAlex 322 FWCI108.10083521

Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update

review Full Text OpenAlex 319 FWCI55.32552997

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

article Full Text OpenAlex 316 FWCI47.52797205

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

article Full Text OpenAlex 314 FWCI45.85706679

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

article Full Text OpenAlex 306 FWCI45.30009836

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

article Full Text OpenAlex 285 FWCI111.19050417